ImmunityBio
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, ImmunityBio sits in the top decile of US sponsors by registered trial count (#393 of 15,742 sponsors by registered trial count).
ImmunityBio: 46 sponsored US clinical trials, 8 recruiting.
ImmunityBio sponsors 46 registered US clinical trials on ClinicalTrials.gov, 8 of them currently recruiting, and 16 completed. 3 of these trials are in Phase 3-4 (later-stage) and 42 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Glioblastoma, with 2 trials.
Top-decile sponsor footprint
ImmunityBio ranks in the top decile of sponsors by registered trial count (#393 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
16 of 30 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (53.3%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
46 total, page 1 of 1
A Study to Assess Anktiva in Patients With Long Covid-19.
NCT07108036
ResQ133A-NMIBC: Intravesical Recombinant Mycobacterium (rMBCG) in Participants With NMIBC Eligible to Receive Intravesical Tice BCG
NCT06800963
ResQ201A: Clinical Trial Of N-803 Plus TISLELIZUMAB And DOCETAXEL Versus DOCETAXEL Monotherapy In Participants With Advanced Or Metastatic Non-Small Cell Lung Cancer
NCT06745908
A Study to Examine Anktiva for the Treatment of COVID-19.
NCT07123727
Study for Subjects With Relapsed/Refractory Non- Hodgkin Lymphoma
NCT05618925
A Phase 2, Open-label, Single-arm Study Of Autologous M-CENK Adoptive Cell Therapy And N-803 (IL-15 Superagonist) In Combination With Gemcitabine In Participants With Recurrent Platinum-Resistant High-Grade Ovarian Cancer
NCT06710288
N-803 and PD-L1 t-haNK Combined With Bevacizumab for Recurrent or Progressive Glioblastoma
NCT06061809
A Study of Intravesical BCG in Combination With ALT-803 in Patients With Non-Muscle Invasive Bladder Cancer
NCT02138734
IBRX-042 In Participants With HPV-Associated Tumors
NCT05976828
Follow up of Intravesical N-803 Plus BCG in BCG-Naive Non-Muscle Invasive Bladder Cancer (NMIBC)
NCT05981131
QUILT-3.076: Study of Autologous M-CENK in Subjects With Locally Advanced or Metastatic Solid Tumors
NCT04898543
Combination Immunotherapy Plus Standard-of-Care Chemotherapy Versus Standard-of-Care Chemotherapy for the Treatment of Locally Advanced or Metastatic Pancreatic Cancer
NCT04390399
QUILT-3.064: PD-L1 t-haNK In Subjects With Locally Advanced Or Metastatic Solid Cancers
NCT04050709
QUILT-3.055: A Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With Immune Checkpoint Inhibitors
NCT03228667
Nogapendekin Alfa Inbakicept for Advanced Non-Small Cell Lung Cancer
NCT03520686
QUILT-3.032: A Multicenter Clinical Trial of Intravesical Bacillus Calmette-Guerin (BCG) in Combination With ALT-803 (N-803) in Patients With BCG Unresponsive High Grade Non-Muscle Invasive Bladder Cancer
NCT03022825
Single Center Study Of N-803 Stimulation On Expansion, Enrichment, Proliferation Of Natural Killer Cells Collected By Apheresis
NCT06040918
HCW9218 for Advanced Pancreatic Cancer
NCT05304936
A Study of Sacituzumab With Chemoimmunotherapy to Treat Advanced Triple-Negative Breast Cancer After Prior Therapies
NCT04927884
COVID-19 Oral and Subcutaneous Vaccination Using a 2nd Generation (E1/E2B/E3-Deleted) Adenovirus Platform in Healthy Volunteers in USA
NCT04732468
A 2nd Generation E1/E2B/E3-Deleted Adenoviral COVID-19 Vaccine: The TCELL VACCINE TRIAL
NCT06022224
COVID-19 Vaccination Using a 2nd Generation (E1/E2B/E3-Deleted) Adenoviral-COVID-19 in Normal Healthy Volunteers
NCT04591717
Study of the Safety of Therapeutic Tx With Immunomodulatory MSC in Adults With COVID-19 Infection Requiring Mechanical Ventilation
NCT04397796
Study of the Safety of Therapeutic Treatment With an Immunomodulatory Agent (N-803) in Adults With COVID-19
NCT04385849
QUILT-3.063: A Study of N-803, haNK and Avelumab in Patients With Merkel Cell Carcinoma That Has Progressed After Checkpoint Therapy
NCT03853317
QUILT 3.071: NANT Colorectal Cancer (CRC) Vaccine
NCT03563157
QUILT-3.080: NANT Pancreatic Cancer Vaccine
NCT03586869
QUILT-3.067: NANT Triple Negative Breast Cancer (TNBC) Vaccine: Molecularly Informed Integrated Immunotherapy in Subjects With TNBC Who Have Progressed on or After Standard-of-care Therapy.
NCT03387085
QUILT-3.090: NANT Squamous Cell Carcinoma (SCC) Vaccine: Subjects With SCC Who Have Progressed
NCT03387111
QUILT-3.070:Pancreatic Cancer Vaccine: Subjects With Pancreatic Cancer Who Have Progressed on or After Standard-of-care Therapy
NCT03387098
QUILT-3.060: NANT Pancreatic Cancer Vaccine: Molecularly Informed Integrated Immunotherapy in Subjects With Pancreatic Cancer Who Have Progressed on or After Standard-of-care Therapy
NCT03329248
QUILT-3.039: NANT Pancreatic Cancer Vaccine: Combination Immunotherapy in Subjects With Pancreatic Cancer Who Have Progressed on or After Standard-of-care Therapy
NCT03136406
QUILT-3.028: Study of haNK™ for Infusion in Subjects With Metastatic or Locally Advanced Solid Tumors
NCT03027128
QUILT-3.009: Patients With Stage III (IIIB) or Stage (IV) Merkel Cell Carcinoma (MCC)
NCT02465957
Efficacy and Safety of Aldoxorubicin Compared to Topotecan in Subjects With Metastatic Small Cell Lung Cancer
NCT02200757
Study to Investigate the Safety and Activity of Aldoxorubicin Plus Ifosfamide/Mesna in Subjects With Metastatic Soft Tissue Sarcoma
NCT02235701
Study to Investigate the Safety and Activity of Aldoxorubicin Plus Gemcitabine in Subjects With Metastatic Solid Tumors
NCT02235688
QUILT-3.018: Neukoplast™ (NK-92) for the Treatment of Refractory or Relapsed Acute Myeloid Leukemia
NCT00900809
A Study to Investigate ALDOXORUBICIN in HIV-infected Subjects With Kaposi's Sarcoma
NCT02029430
Phase 2 Study to Investigate the Efficacy and Safety of Aldoxorubicin in Subjects With Glioblastoma
NCT02014844
Phase 3 Study to Treat Patients With Soft Tissue Sarcomas
NCT02049905
Study to Investigate the Pharmacolkinetics of Aldoxorubicin (INNO-206;DOXO-EMCH) Administered as a 30 Minute Infusion Every 3 Weeks in Subjects With Advanced Solid Tumors
NCT01706835
Phase 1b Study to Investigate the Safety and Maximum Tolerated Dose of Aldoxorubicin (INNO-206) Plus Doxorubicin HCL in Subjects With Advanced Solid Tumors
NCT01673438
Pilot Phase 2 Study to Investigate the Preliminary Efficacy and Safety of INNO-206 in Advanced Pancreatic Cancer
NCT01580397
Preliminary Efficacy and Safety of INNO-206 Compared to Doxorubicin in Advanced Soft Tissue Sarcoma
NCT01514188
Safety and Maximum Tolerated Dose (MTD) Study of INNO-206 in Subjects With Advanced Solid Tumors
NCT01337505
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 27 |
| Phase 2 | 15 |
| Phase 3 | 3 |
Therapeutic Areas
What is open in the ImmunityBio pipeline
8 recruiting of 46 indexed (17% open); 16 completed (35%).
Phase mix: 3 late (III/IV) vs 42 early (I/II) (early-phase heavy).
Top condition: Glioblastoma (2 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
ImmunityBio: open-pipeline peers nationwide
Peers matched on 46 registered trials and 17% open enrollment, not the therapeutic-area sidebar.
ImmunityBio sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 46 trials (± recruiting share)
- Baxter Healthcare Corporation · 46 trials · 2% recruiting
- National Institute of Nursing Research (NINR) · 46 trials · 0% recruiting
- University of Maryland, College Park · 46 trials · 22% recruiting
- New York Medical College · 47 trials · 34% recruiting
Sponsors near 17% open enrollment (± trial volume)
- Old Dominion University · 17% recruiting · 23 trials
- Texas Tech University · 17% recruiting · 69 trials
- TransMedics · 17% recruiting · 23 trials
- Memorial Sloan Kettering Cancer Center · 17% recruiting · 1,884 trials
Related
What to do with this ImmunityBio page
46 registered trials is a research-attention snapshot, not an endorsement of ImmunityBio or any single study.
- 8 of ImmunityBio's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Glioblastoma is the condition ImmunityBio studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Glioblastoma trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
ImmunityBio pipeline card: 46 registered trials from official public datasets.Report a data error.